CN113876919B - Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof - Google Patents
Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof Download PDFInfo
- Publication number
- CN113876919B CN113876919B CN202111226617.1A CN202111226617A CN113876919B CN 113876919 B CN113876919 B CN 113876919B CN 202111226617 A CN202111226617 A CN 202111226617A CN 113876919 B CN113876919 B CN 113876919B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, a pharmaceutical preparation and application thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for promoting blood circulation and removing blood stasis comprises the following raw material medicines: angelica, rhizoma sparganii, curcuma zedoary, selfheal, moutan bark, red peony root, achyranthes root, kelp, seaweed, frankincense, corydalis tuber, rhizoma cyperi and ginger. The medicinal preparation is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials. The application refers to the application of the traditional Chinese medicine composition and the pharmaceutical preparation in preparing medicines for treating and/or preventing the hysteromyoma. The traditional Chinese medicine composition provided by the invention has the advantages of obvious curative effect, small toxic and side effects, quick response, easily available materials, lower cost and good industrial application prospect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, a pharmaceutical preparation and application thereof.
Background
Uterine fibroids are common benign tumors in women, and are composed of smooth muscle and connective tissue, so they are also called uterine fibroids and uterine leiomyoma. More than 90% of uterine fibroids grow in the body of the uterus. It is mostly a mass formed by the coagulation of deficiency of healthy qi, disorder of qi and blood, stagnation of qi and blood, etc. The clinical manifestations mainly include anemia, menorrhagia, pain, menostaxis, abnormal leucorrhea, abortion, infertility, rectal and bladder compression symptoms, severe patients will affect the daily life and psychology of patients, and in recent years, the incidence of the disease tends to increase due to various factors such as changes in the surrounding environment, changes in dietary structure, and accelerated work pace.
The exact cause of uterine fibroids is not currently understood, and the factor hysteromyoma occurs mostly in women between the ages of 30-50 years (70% -80%), rarely in prepubertal, and atrophy or regressions after menopause, suggesting that its occurrence may be related to female hormones. In addition, genetic factors have been shown to affect the incidence of uterine fibroids.
Western medicine believes that surgical treatment is still the best treatment for patients with symptomatic uterine fibroids at present. The operative procedures used include total hysterectomy, sub-total hysterectomy, myoma removal, endoscopic myoma removal and hysterectomy, and procedures that only preserve the endometrium. These surgical methods often have problems of impairment of female menstruation and fertility, great physical trauma, high surgical costs, etc. At present, the treatment medicines are mainly hormone medicines, so that the toxic and side effects of the medicines are often large, and once the medicines occur, the medicines bring great burden to the body of a patient.
TCM has no name of hysteromyoma, and is classified into "mass" and "stone mass" according to its clinical manifestations. The stone is first found in Huangdi's classic on medicine, where the stone is born in the uterus, cold qi is confined to the subglottic … …, and when the blood is discharged but not discharged, bloody stasis is left behind, which is good for the heart and is not in the morning. "Mass" is originally observed in "jin Kui Yao L ü e" the possibility of a woman having a persistent disease and moving fetus on the umbilicus after failing to pass for March, which is an illness of the aeipathia. "Mass" and "abdominal mass" are called "mass" together. According to the traditional Chinese medicine, the uterine fibroid is mainly caused by dysfunction of kidney, liver and spleen, so that blood stasis or phlegm-dampness blocks uterus, and mass is formed for a long time. The traditional Chinese medicine treats the disease according to the constitution and different syndrome types of patients, can achieve the purpose of treating the disease and seeking the root, dispels pathogenic factors and does not hurt the body resistance, and has the advantages of good curative effect and good prognosis.
Chinese patent CN2017111706924 discloses a traditional Chinese medicine composition for treating hysteromyoma, which comprises the following traditional Chinese medicine raw materials in parts by weight: 10-30 parts of angelica sinensis, 10-20 parts of ligusticum wallichii, 10-20 parts of bighead atractylodes rhizome, 5-15 parts of cassia twig, 10-20 parts of purslane, 10-20 parts of curcuma zedoary, 5-15 parts of coptis chinensis, 5-15 parts of peach kernel, 5-15 parts of achyranthes bidentata, 10-20 parts of poria cocos, 10-20 parts of madder, 5-15 parts of rush, 10-40 parts of rhizoma sparganii, 10-20 parts of cyrtomium rhizome, 10-20 parts of fried schizonepeta spike, 5-15 parts of exocarpium citri rubrum, 10-20 parts of anemone, 10-20 parts of cotton root, 5-15 parts of radix polygonati officinalis, 10-20 parts of baked ginger, 10-40 parts of leonurus and 5-15 parts of liquorice, but the treatment effect is not specifically described.
Therefore, the development of a traditional Chinese medicine composition which has a remarkable treatment effect and can replace surgery and hormone medicines for treating the uterine fibroids is urgently needed.
Disclosure of Invention
The invention provides a traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, a pharmaceutical preparation containing the composition and application thereof, aiming at the problems of large trauma, poor prognosis, large side effect of hormone medicine treatment and the like in the operation treatment of hysteromyoma in the prior art. The traditional Chinese medicine composition is re-formulated after researching the pharmacology of the traditional Chinese medicine, and has the advantages of obvious curative effect, small toxic and side effects and quick response when being used for treating the hysteromyoma.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
the invention discloses a traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, which consists of the following raw material medicines:
angelica, rhizoma sparganii, curcuma zedoary, selfheal, moutan bark, red peony root, achyranthes root, kelp, seaweed, frankincense, corydalis tuber, rhizoma cyperi and ginger.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight:
6-12 parts of angelica, 6-12 parts of rhizoma sparganii, 6-12 parts of curcuma zedoary, 6-12 parts of moutan bark, 6-12 parts of red paeony root, 6-12 parts of achyranthes root, 6-12 parts of corydalis tuber, 6-12 parts of rhizoma cyperi, 20-26 parts of selfheal, 20-26 parts of seaweed, 20-26 parts of kelp, 2-8 parts of frankincense and 1-7 parts of ginger.
Further preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight:
6-10 parts of angelica, 6-10 parts of rhizoma sparganii, 6-10 parts of curcuma zedoary, 6-10 parts of moutan bark, 6-10 parts of red paeony root, 6-10 parts of achyranthes root, 6-10 parts of corydalis tuber, 6-10 parts of rhizoma cyperi, 20-24 parts of selfheal, 20-24 parts of seaweed, 20-24 parts of kelp, 2-6 parts of frankincense and 1-5 parts of ginger.
Further preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight:
6-8 parts of angelica, 6-8 parts of rhizoma sparganii, 6-8 parts of curcuma zedoary, 6-8 parts of moutan bark, 6-8 parts of red peony root, 6-8 parts of achyranthes root, 6-8 parts of corydalis tuber, 6-8 parts of rhizoma cyperi, 20-22 parts of selfheal, 20-22 parts of seaweed, 20-22 parts of kelp, 2-4 parts of frankincense and 1-3 parts of ginger.
The common selfheal fruit spike is a dry fruit spike of the common selfheal fruit spike of the Labiatae, is commonly used for treating various malignant tumors in modern medicine, and has the effects of clearing away heat and toxic materials, soothing liver and regulating qi, clearing and activating the channels and collaterals, softening and resolving hard mass, eliminating stagnation and reducing swelling, and clearing damp.
Thallus laminariae, dry thallus of herba Zosterae Marinae of Laminariaceae; the Sargassum is dried body of Sargassum pallidum or Cyrtymenia Sparsa of Sargassaceae. Both the Chinese medicinal materials have the effects of softening hardness to dissipate stagnation, dissolving phlegm and promoting diuresis, and researches show that the Chinese medicinal materials can strengthen the anti-cancer and anti-tumor capability of the body, and can effectively improve the symptoms of diabetes and relieve stress.
Angelica sinensis is the dry root of Angelica sinensis of Umbelliferae, and it can tonify blood and activate blood, and it can dredge meridians and collaterals.
Rhizoma corydalis is dried tuber of corydalis tuber of Papaveraceae; the Olibanum is resin exuded from bark of Boswellia serrata of Burseraceae and plants of the same genus; the rhizoma Sparganii is dry tuber of Sparganium stoloniferum of Sparganiaceae; the Curcumae rhizoma is dried rhizome of Curcuma zedoaria, Curcuma kwangsiensis or Curcuma wenyujin belonging to Zingiberaceae family. Corydalis tuber, frankincense, common burreed rhizome and zedoary activate blood circulation to dissipate blood stasis, and promote qi circulation to relieve pain.
Cortex moutan is dried root bark of Paeonia suffruticosa Andr of Ranunculaceae; radix Paeoniae Rubra is dried root of Paeonia lactiflora pall or Paeonia veitchii pall of Ranunculaceae. Both of them can cool blood and activate blood circulation.
Rhizoma Cyperi is dried rhizome of Cyperus rotundus L of Cyperaceae, has effects of regulating qi, resolving stagnation, regulating menstruation, and relieving pain, and is used for treating stagnation of qi due to depression of liver, chest, hypochondrium, abdominal pain, menoxenia, amenorrhea, and dysmenorrhea.
Achyranthis radix is the dry root of Achyranthis radix of Amaranthaceae, and has effects of nourishing liver and invigorating kidney, strengthening tendons and bones, dredging channels and collaterals, dispelling blood stasis, and guiding medicine downward.
Ginger is the fresh rhizome of Zingiber officinale of Zingiberaceae, and is used for regulating stomach qi.
The medicines are combined to have the effects of regulating qi, relieving pain, promoting blood circulation, removing blood stasis, softening hardness and dissipating stagnation.
The invention also discloses a pharmaceutical preparation for treating hysteromyoma, which is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
Preferably, the pharmaceutical preparation is an oral dosage form, and the oral dosage form comprises granules, tablets, capsules, powder, pills, syrup, mixture or paste.
Preferably, the pharmaceutical preparation is a granule for treating hysteromyoma.
Preferably, the preparation method of the granules comprises the following steps:
s1, weighing the bulk drugs of the traditional Chinese medicine composition according to the formula, adding water for decoction, filtering, and combining the filtrates;
s2, concentrating the filtrate obtained in the step S1 under reduced pressure, adding auxiliary materials, mixing uniformly, drying, adding the auxiliary materials, mixing uniformly, and granulating to obtain the granules.
Preferably, the auxiliary material in step S2 is at least one of dextrin, maltodextrin, betacyclodextrin, lactose and soluble starch.
The invention also discloses an application of the traditional Chinese medicine composition and the pharmaceutical preparation in preparing medicines for treating and/or preventing hysteromyoma.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention provides a traditional Chinese medicine composition for promoting blood circulation and removing blood stasis, which has the main effects of soothing liver and tonifying qi, and promoting blood circulation and removing blood stasis, and particularly has an obvious treatment effect on patients with liver-qi stagnation and qi and blood stasis.
2. The invention provides a traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, which has an obvious effect of treating hysteromyoma and a quick curative effect, and enables patients to be free from operation pain.
3. The raw material medicines of the traditional Chinese medicine composition with the effects of promoting blood circulation and removing blood stasis provided by the invention are natural medicinal plants verified by clinical tests for many years, are high in biological safety, free of toxic and side effects, easily available in materials, low in treatment cost and suitable for industrial production.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not to be limited to the specific embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It should be noted that the raw materials used in the present invention are all common commercial products, the sources thereof are not particularly limited, and some of the raw materials are shown in table 1.
TABLE 1
Examples 1 to 5A granule for treating hysteromyoma
Example 1
Crude drug prescription:
the preparation method comprises the following steps: s1, cleaning the 13 traditional Chinese medicinal materials, removing impurities, drying in the air, adding water into a multifunctional extraction tank, decocting twice, adding water 10 times of the total medicinal materials for the first time, decocting for 2 hours, taking decoction, filtering, adding water 8 times of the total medicinal materials for the second time, decocting for 1 hour, taking decoction, filtering, and combining the two filtrates.
S2, concentrating the filtrate obtained in the step S1 under reduced pressure to a concentrated solution with the relative density of 1.05-1.10 at 60 ℃, adding dextrin with the crude drug amount of 10%, uniformly mixing, spray drying, adding dextrin with the crude drug amount of 15%, uniformly mixing, and granulating to obtain the granules.
Example 2
This example is different from example 1 in the crude drug formulation, and the other preparation methods are the same as example 1.
Crude drug prescription:
example 3
This example is different from example 1 in the crude drug formulation, and the other preparation methods are the same as example 1.
Crude drug prescription:
example 4
This example is different from example 1 in the crude drug formulation, and the other preparation methods are the same as example 1.
Crude drug prescription:
example 5
This example is different from example 1 in the crude drug formulation, and the other preparation methods are the same as example 1.
Crude drug prescription:
comparative example 1
This comparative example is different from example 1 in the crude drug formulation, and the rest of the preparation method is the same as example 1.
Crude drug prescription:
comparative example 2
This comparative example is different from example 1 in the crude drug formulation, and the rest of the preparation method is the same as example 1.
Crude drug prescription:
comparative example 3
This comparative example is different from example 1 in the crude drug formulation, and the rest of the preparation method is the same as example 1.
Crude drug prescription:
and (3) evaluating the drug effect:
SPF grade adult female non-pregnant SD rats weighing 180-220g were acclimatized for 3 days and randomized into 10 groups of 10 animals each. Except the blank group, 1.35mg/kg of diethylstilbestrol liquid medicine is administered to other groups by intragastric administration every day, and 1.0 mg/progesterone injection is injected into the outer side of the lower limbs of one, three or five weeks every week for 5 weeks continuously; starting from the 4 th week, 0.9mg/kg of epinephrine hydrochloride injection is injected subcutaneously, chronic unpredictable stimulation is given after 4 hours (60 db noise stimulation is continued for 3 hours, day and night are reversed, swimming is carried out in an ice water bath at 5-10 ℃ for 4min, tail suspension is carried out for 10min, drying is carried out in a drying oven at 50 ℃ for 10min, 1 stimulation is randomly given every day, and each stimulation in the whole week is guaranteed to be not less than 2 times), and the continuous 2 weeks are carried out. The blank group was administered 2ml of physiological saline daily, and 0.05 ml/body of physiological saline was injected into the lateral muscles of the lower limbs every one, three, and five weeks for 5 weeks. Starting from the first week of molding, drug treatment was administered 2 hours after molding, and 3.5g/kg of the corresponding drug was administered to groups 1 to 3 and examples 1 to 5 by intragastric administration, and equal volumes of physiological saline were administered to the blank group and the model group, respectively.
1. Influence on uterine coefficients
After the administration, the body mass of each group of rats is weighed, the uterus is taken out after the sacrifice, the wet weight of the uterus is weighed, and the uterus coefficient is calculated, and the result is shown in table 2.
The uterine coefficient is [ uterine mass (g)/volume mass (g) ].
TABLE 2 uterine coefficient measurement results (
n＝10)
Note: p <0.05 compared to blank and Δ P <0.05 compared to model
2. Effect on uterine smooth muscle layer thickness
Fixing by perfusion with 10% paraformaldehyde, taking out uterine tissue, dehydrating with ethanol and xylene, embedding in paraffin to obtain blocks, slicing, staining, sealing, observing under optical lens, and collecting image. For each sample, 5 fields were randomly selected for photographic observation, and the thickness of the smooth muscle layer was calculated and averaged to obtain the final result, which is shown in table 3.
TABLE 3 measurement of thickness of uterine smooth muscle layer in rat: (
n＝10)
Note: p <0.05 compared to blank and Δ P <0.05 compared to model
As can be seen from tables 2 and 3, compared with the blank group, the uterine coefficient and smooth muscle layer thickness of the model group are obviously increased, and the difference has statistical significance, which indicates that the rat model of the uterine fibroids is successfully established. Compared with a model group, the example group of the invention can obviously reduce the uterine coefficient and the thickness of a smooth muscle layer, and the difference has statistical significance; in the comparative example group, the effect of reducing uterine coefficient and thickness of smooth muscle layer was not significant in the case of the Chinese medicinal composition whose crude drug formulation was not within the scope of the present invention.
Finally, it should be noted that the above-mentioned contents are only used for illustrating the technical solutions of the present invention, and do not limit the protection scope of the present invention, and those skilled in the art can make simple modifications or equivalent substitutions on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (9)
1. A traditional Chinese medicine composition for promoting blood circulation and removing blood stasis is characterized by comprising the following raw material medicines in parts by weight:
6-12 parts of angelica, 6-12 parts of rhizoma sparganii, 6-12 parts of curcuma zedoary, 6-12 parts of moutan bark, 6-12 parts of red paeony root, 6-12 parts of achyranthes root, 6-12 parts of corydalis tuber, 6-12 parts of rhizoma cyperi, 20-26 parts of selfheal, 20-26 parts of seaweed, 20-26 parts of kelp, 2-8 parts of frankincense and 1-7 parts of ginger.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight:
6-10 parts of angelica, 6-10 parts of rhizoma sparganii, 6-10 parts of curcuma zedoary, 6-10 parts of moutan bark, 6-10 parts of red paeony root, 6-10 parts of achyranthes root, 6-10 parts of corydalis tuber, 6-10 parts of rhizoma cyperi, 20-24 parts of selfheal, 20-24 parts of seaweed, 20-24 parts of kelp, 2-6 parts of frankincense and 1-5 parts of ginger.
3. The traditional Chinese medicine composition according to claim 2, which is characterized by comprising the following raw material medicines in parts by weight:
6-8 parts of angelica, 6-8 parts of rhizoma sparganii, 6-8 parts of curcuma zedoary, 6-8 parts of moutan bark, 6-8 parts of red paeony root, 6-8 parts of achyranthes root, 6-8 parts of corydalis tuber, 6-8 parts of rhizoma cyperi, 20-22 parts of selfheal, 20-22 parts of seaweed, 20-22 parts of kelp, 2-4 parts of frankincense and 1-3 parts of ginger.
4. A pharmaceutical preparation for treating hysteromyoma, which is prepared from the Chinese medicinal composition of any one of claims 1 to 3 and pharmaceutically acceptable auxiliary materials.
5. The pharmaceutical formulation of claim 4, wherein the pharmaceutical formulation is an oral dosage form comprising granules, tablets, capsules, powders, pills, syrups, mixtures or pastes.
6. The pharmaceutical formulation of claim 5, wherein the pharmaceutical formulation is a granule for treating uterine fibroids.
7. The pharmaceutical formulation of claim 6, wherein the method of preparing the granules comprises the steps of:
s1, weighing the bulk drugs of the traditional Chinese medicine composition according to the formula, adding water for decoction, filtering, and combining the filtrates;
s2, concentrating the filtrate obtained in the step S1 under reduced pressure, adding auxiliary materials, mixing uniformly, drying, adding the auxiliary materials, mixing uniformly, and granulating to obtain the granules.
8. The pharmaceutical formulation of claim 7, wherein the excipient is at least one of dextrin, maltodextrin, betacyclodextrin, lactose and soluble starch in step S2.
9. Use of the Chinese medicinal composition according to any one of claims 1 to 3 and the pharmaceutical preparation according to any one of claims 5 to 8 for the preparation of a medicament for the treatment and/or prevention of uterine fibroids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111226617.1A CN113876919B (en) | 2021-10-21 | 2021-10-21 | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111226617.1A CN113876919B (en) | 2021-10-21 | 2021-10-21 | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113876919A CN113876919A (en) | 2022-01-04 |
| CN113876919B true CN113876919B (en) | 2022-08-23 |
Family
ID=79004092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111226617.1A Active CN113876919B (en) | 2021-10-21 | 2021-10-21 | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113876919B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897855A (en) * | 2010-07-14 | 2010-12-01 | 合肥今越制药有限公司 | Medicament for treating uterine myoma |
-
2021
- 2021-10-21 CN CN202111226617.1A patent/CN113876919B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101897855A (en) * | 2010-07-14 | 2010-12-01 | 合肥今越制药有限公司 | Medicament for treating uterine myoma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113876919A (en) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6696094B2 (en) | Herbal pharmaceutical composition for treatment of HIV/AIDS patients | |
| CN101780160B (en) | Traditional Chinese medicine preparation for treating gynecological disease and preparation method thereof | |
| CN110013470B (en) | Application of Shenbao tablet in preparing medicine for treating sequelae of pelvic inflammatory disease | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN101708297A (en) | Medicament for treating gout disease | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN104815318A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN113876919B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis, pharmaceutical preparation and application thereof | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN112755140B (en) | Pharmaceutical composition for treating gouty arthritis and preparation method and application thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN112274619B (en) | Composition for relieving dysmenorrhea and application of composition in preparation of medicines, health-care products or foods | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN1814196A (en) | Chinese medicine composition for treating functional metrorrhagia and use thereof | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| GB2402062A (en) | Pharmaceutical composition for the prophylaxis or treatment of osteoporosis | |
| CN104436121B (en) | It is a kind of to treat irregular menstruation, small distention and fullness in the abdomen, the medicine to fail to be impregnated for a long time | |
| CN102145099A (en) | Traditional Chinese medicine for treating infertility caused by liver stagnation | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN115814040B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN111214584B (en) | Traditional Chinese medicine composition for tonifying kidney and benefiting liver as well as preparation method and application thereof | |
| CN115581751B (en) | A Chinese medicinal composition for treating chronic hepatitis B, and its preparation method | |
| CN115581749B (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |